Quantamental Technologies LLC grew its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 71.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,579 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,077 shares during the quarter. Quantamental Technologies LLC’s holdings in Jazz Pharmaceuticals were worth $369,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in JAZZ. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in Jazz Pharmaceuticals during the first quarter worth about $25,000. Prime Capital Investment Advisors LLC purchased a new stake in Jazz Pharmaceuticals during the first quarter worth about $27,000. Carroll Financial Associates Inc. increased its stake in Jazz Pharmaceuticals by 166.7% during the first quarter. Carroll Financial Associates Inc. now owns 200 shares of the specialty pharmaceutical company’s stock worth $28,000 after purchasing an additional 125 shares during the period. Enlightenment Research LLC purchased a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $37,000. Finally, First Hawaiian Bank increased its stake in Jazz Pharmaceuticals by 42.2% during the fourth quarter. First Hawaiian Bank now owns 320 shares of the specialty pharmaceutical company’s stock worth $39,000 after purchasing an additional 95 shares during the period. 94.73% of the stock is currently owned by institutional investors.
NASDAQ:JAZZ traded down $0.66 during trading hours on Friday, hitting $136.76. The company’s stock had a trading volume of 447,151 shares, compared to its average volume of 625,601. The stock has a market capitalization of $7.79 billion, a price-to-earnings ratio of 11.17, a PEG ratio of 1.11 and a beta of 1.16. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.01 and a current ratio of 3.15. Jazz Pharmaceuticals PLC has a 52-week low of $113.52 and a 52-week high of $184.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.83 by $0.44. The firm had revenue of $508.19 million during the quarter, compared to analysts’ expectations of $466.55 million. Jazz Pharmaceuticals had a return on equity of 27.35% and a net margin of 24.88%. Jazz Pharmaceuticals’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.98 earnings per share. On average, analysts predict that Jazz Pharmaceuticals PLC will post 13.24 EPS for the current year.
A number of analysts recently weighed in on JAZZ shares. HC Wainwright restated a “hold” rating and set a $153.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, May 10th. ValuEngine upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 8th. Mizuho upped their target price on shares of Jazz Pharmaceuticals from $146.00 to $148.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 8th. BMO Capital Markets upped their price target on Jazz Pharmaceuticals from $206.00 to $208.00 and gave the company an “outperform” rating in a report on Wednesday, May 8th. Finally, Zacks Investment Research downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, May 6th. Two analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $182.41.
In other news, SVP Paul Treacy sold 874 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $139.50, for a total value of $121,923.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Matthew P. Young sold 1,916 shares of the firm’s stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $131.46, for a total value of $251,877.36. The disclosure for this sale can be found here. Insiders sold 11,668 shares of company stock valued at $1,606,567 in the last quarter. 3.90% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Jazz Pharmaceuticals PLC (JAZZ) Position Lifted by Quantamental Technologies LLC” was first published by Sundance Herald and is owned by of Sundance Herald. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://sundanceherald.com/2019/05/24/quantamental-technologies-llc-increases-stake-in-jazz-pharmaceuticals-plc-jazz.html.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Featured Article: Call Option
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.